RECRUITING

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Talk to us

Conditions

Relapsed or Refractory Multiple MyelomaMultiple myelomaRRMMMeziVdPVdCC92480pomalidomidebortezomibdexamethasonemezigdomide

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.

Official Title

A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-1

Quick Facts

Study Start:2022-09-20
Study Completion:2033-11-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05519085

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
855-907-3286
Clinical.Trials@bms.com
First line of the email MUST contain the NCT# and Site #.
CONTACT

Principal Investigator

Bristol-Myers Squibb
STUDY_DIRECTOR
Bristol-Myers Squibb

Study Locations (Sites)

Cancer and Blood Specialty Clinic
Los Alamitos, California, 90720
United States
Sharp Memorial Hospital
San Diego, California, 92123
United States
Private Practice - Dr. James R. Berenson
West Hollywood, California, 90069
United States
Local Institution - 0381
Aurora, Colorado, 80045
United States
Local Institution - 0380
Farmington, Connecticut, 06030
United States
Advanced Research
Coral Springs, Florida, 33321
United States
Local Institution - 0403
Fort Myers, Florida, 33901
United States
Local Institution - 0401
Saint Petersburg, Florida, 33705
United States
Local Institution - 0402
West Palm Beach, Florida, 33401
United States
University Cancer Blood Ctr
Athens, Georgia, 30607
United States
Local Institution - 0048
Marietta, Georgia, 30060
United States
Central Care Cancer Center - Garden City
Garden City, Kansas, 67846
United States
University of Kansas Medical Center
Westwood, Kansas, 66205
United States
Our Lady of the Lake RMC
Baton Rouge, Louisiana, 70808
United States
Tulane Cancer Center
New Orleans, Louisiana, 70112
United States
Local Institution - 0385
Shreveport, Louisiana, 71103
United States
Sinai Hospital Of Baltimore
Baltimore, Maryland, 21215
United States
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215
United States
University of Michigan
Ann Arbor, Michigan, 48109
United States
Local Institution - 0364
Detroit, Michigan, 48202
United States
Local Institution - 0410
Minneapolis, Minnesota, 55404
United States
Hattiesburg Clinic Hematology/Oncology
Hattiesburg, Mississippi, 39401
United States
Local Institution - 0242
Jackson, Mississippi, 39213
United States
Astera Cancer Care
East Brunswick, New Jersey, 08816
United States
Local Institution - 0363
Ridgewood, New Jersey, 07450
United States
University of New Mexico Comprehensive Cancer Center
Albuquerque, New Mexico, 87131
United States
Local Institution - 0372
Bronx, New York, 10469
United States
Local Institution - 0245
Buffalo, New York, 14215
United States
Northwell Health/ RJ Zuckerberg Cancer Center
Lake Success, New York, 11042
United States
Local Institution - 0373
New Hyde Park, New York, 11042
United States
New York Cancer and Blood Specialists
New York, New York, 10028
United States
Rochester General Hospital
Rochester, New York, 14621
United States
New York Cancer and Blood Specialists
Shirley, New York, 11967
United States
Local Institution - 0274
Williamsville, New York, 14221
United States
Duke Cancer Institute
Durham, North Carolina, 27710
United States
Local Institution - 0400
Cincinnati, Ohio, 45242
United States
Fairview Hospital
Cleveland, Ohio, 44111
United States
Cleveland Clinic
Cleveland, Ohio, 44195
United States
Cleveland Clinic - Hillcrest Hospital
Mayfield Heights, Ohio, 44124
United States
Lehigh Valley Health Network
Allentown, Pennsylvania, 18103
United States
Local Institution - 0264
York, Pennsylvania, 17403
United States
The West Clinic, PLLC dba West Cancer Center
Germantown, Tennessee, 38138
United States
Local Institution - 0378
Abilene, Texas, 79606
United States
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030
United States
Mays Cancer Center
San Antonio, Texas, 78229
United States
Local Institution - 0409
San Antonio, Texas, 78240
United States
Utah Cancer Specialists
Salt Lake City, Utah, 84106
United States
Hematology Oncology Associates of Fredericksburg
Fredericksburg, Virginia, 22408
United States
Local Institution - 0408
Norfolk, Virginia, 23502
United States
Local Institution - 0399
Roanoke, Virginia, 24014
United States
VA Puget Sound Health Care System
Seattle, Washington, 98108
United States
Local Institution - 0293
Seattle, Washington, 98109
United States
Local Institution - 0097
Spokane, Washington, 99208
United States
Local Institution - 0411
Vancouver, Washington, 98684
United States
Local Institution - 0220
Madison, Wisconsin, 53792
United States

Collaborators and Investigators

Sponsor: Celgene

  • Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-09-20
Study Completion Date2033-11-30

Study Record Updates

Study Start Date2022-09-20
Study Completion Date2033-11-30

Terms related to this study

Keywords Provided by Researchers

  • Multiple myeloma
  • RRMM
  • MeziVd
  • PVd
  • CC92480
  • pomalidomide
  • bortezomib
  • dexamethasone
  • mezigdomide

Additional Relevant MeSH Terms

  • Relapsed or Refractory Multiple Myeloma